Mercedes Lobera

1 ta ish

GlaxoSmithKline (United States)

1. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

   Jennifer L. Guerriero, Alaba Sotayo, Holly Ponichtera +11

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.056969